• Onconetix posted net loss of $4.21 million, narrowing from year-earlier net loss applicable to common stockholders of $9.72 million.
• Revenue fell 78.9% to $21,457, swinging gross profit to gross loss of $1,655.
• Operating loss narrowed to $10.23 million as total operating expenses fell 19% to $10.22 million, including goodwill impairment of $8.13 million.
• Other income rose 49.3% to $6.01 million on gains tied to fair-value changes in Series D and Series E derivative liabilities.
• Cash totaled $3.7 million at March 31, 2026; Onconetix said balance was not sufficient to fund operations through end of December 2026 while it continues to commercialize Proclarix and pursue Realbotix share-exchange closing conditions, including at least $12.5 million in Net Cash.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-055483), on May 13, 2026, and is solely responsible for the information contained therein.